Alder Biopharmaceuticals (NASDAQ:ALDR) Stock Rating Lowered by BMO Capital Markets

BMO Capital Markets lowered shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from an outperform rating to a market perform rating in a report published on Monday morning, The Fly reports.

A number of other research analysts have also recently commented on the stock. Svb Leerink started coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They set an outperform rating for the company. Credit Suisse Group restated a neutral rating on shares of Alder Biopharmaceuticals in a research note on Wednesday, July 10th. Zacks Investment Research upgraded shares of Alder Biopharmaceuticals from a hold rating to a strong-buy rating and set a $11.00 price target for the company in a research note on Friday, August 9th. Leerink Swann started coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They set an outperform rating and a $21.00 price target for the company. Finally, BidaskClub cut shares of Alder Biopharmaceuticals from a sell rating to a strong sell rating in a research note on Saturday, August 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $17.61.

Shares of ALDR opened at $18.66 on Monday. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -3.83 and a beta of 2.56. The company has a quick ratio of 8.94, a current ratio of 8.94 and a debt-to-equity ratio of 1.74. Alder Biopharmaceuticals has a 12 month low of $8.39 and a 12 month high of $18.90. The company has a 50-day moving average price of $10.03 and a two-hundred day moving average price of $11.56.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.27. Equities research analysts expect that Alder Biopharmaceuticals will post -4.13 EPS for the current fiscal year.

In other news, Director Jeffrey T. L. Smith sold 32,728 shares of Alder Biopharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $18.44, for a total value of $603,504.32. Following the completion of the transaction, the director now owns 27,999 shares in the company, valued at $516,301.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 15.40% of the company’s stock.

Large investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale raised its stake in shares of Alder Biopharmaceuticals by 166.9% in the second quarter. DekaBank Deutsche Girozentrale now owns 64,600 shares of the biopharmaceutical company’s stock valued at $730,000 after acquiring an additional 40,400 shares during the last quarter. TD Asset Management Inc. raised its stake in shares of Alder Biopharmaceuticals by 4.2% in the first quarter. TD Asset Management Inc. now owns 220,064 shares of the biopharmaceutical company’s stock valued at $3,004,000 after acquiring an additional 8,881 shares during the last quarter. Fulcrum Capital LLC bought a new position in shares of Alder Biopharmaceuticals in the second quarter valued at approximately $127,000. Artal Group S.A. raised its stake in shares of Alder Biopharmaceuticals by 70.0% in the second quarter. Artal Group S.A. now owns 850,000 shares of the biopharmaceutical company’s stock valued at $10,005,000 after acquiring an additional 350,000 shares during the last quarter. Finally, Quantamental Technologies LLC bought a new position in shares of Alder Biopharmaceuticals in the second quarter valued at approximately $156,000.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Further Reading: What is an overbought condition?

The Fly

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.